topSkip to main content

Menu, Secondary

Menu Trigger


MU Research Reactor Supplying Radioisotope for New FDA-approved Cancer Therapy

The U.S. Food and Drug Administration has approved a radioisotope-based drug, Lutathera® to treat certain types of tumors that can occur in the gastrointestinal tract and pancreas. 

The University of Missouri’s Research Reactor (MURR®) is the sole U.S. supplier of radioisotope lutetium-177 (Lu-177), which was developed by Advanced Accelerator Applications, S.A., a Novartis company.

“I am delighted that MURR’s research scientists have played such an integral role in promoting the merits of Lu-177 and for the ultimate success achieved by Lutathera®,” said David Robertson, director of research for MURR.

“Research and discoveries made at MURR and across campus will continue to improve the health and lives of citizens of Missouri, the nation and the world” said Mark McIntosh, vice president for research and economic development at the UM System and vice chancellor for research, graduate studies and economic development at MU. “Being the nation’s sole supplier for the active ingredient in a commercially approved cancer therapy such as Lutathera® is a pride point for MU and a responsibility the MURR team takes very seriously.”

“Successes like these pull us all together, from researchers to reactor operations to the entire production and supporting teams,” said Matt Sanford, MURR interim executive director. “We know we are making a difference in the lives of cancer patients every single day.”

This work highlights the capabilities of MURR, a crucial component to research at the university for more than 50 years. Operating 6.5 days a week, 52 weeks a year, scientists from across the campus use the 10-megawatt facility to not only provide crucial radioisotopes for clinical settings globally, but also to date artifacts, improve medical diagnostic tools and prevent illness.

Lutathera® is a trademark of Advanced Accelerator Applications. Full prescribing information for Lutathera® can be found here.

MU Research Reactor Supplying Radioisotope for New FDA-approved Cancer Therapy was originally published on the University of Missouri website.